Bao Pharma-B (02659) Receives NMPA Approval to Launch Clinical Trial of KJ101 for Gastric Mucus Removal

Bulletin Express03-12

Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B, 02659) announced that the National Medical Products Administration (NMPA) has cleared the company to initiate clinical trials of KJ101—its recombinant human chymotrypsin—for the dissolution and removal of gastric mucus during gastroscopy.

KJ101 is positioned as China’s first recombinant human chymotrypsin produced via synthetic biology. Developed with the company’s proprietary yeast-fermentation platform, the drug candidate is designed to eliminate animal-derived inputs, offering higher purity, no animal-origin virus risk, no allergenicity, and minimal batch variability.

Chymotrypsin, a protease capable of rapidly hydrolyzing proteins, is routinely applied in respiratory medicine, surgery, gastroenterology, and other departments to remove necrotic tissue and improve wound visibility. The new study focuses on enhancing visibility and efficiency during gastroscopy by clearing accumulated gastric mucus.

In February 2025, KJ101 secured its initial Investigational New Drug (IND) approval for wound-healing indications such as burns, surgical incisions, pressure ulcers, and diabetic foot ulcers, and a Phase II trial (CTR20252263) commenced in July 2025.

The company cautioned that clinical results, regulatory timelines, and eventual commercialization remain uncertain, and advised shareholders and potential investors to exercise prudence when trading its shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157341579?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 12:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157341579","market":"us","top_or_hot":-1,"title":"Bao Pharma-B (02659) Receives NMPA Approval to Launch Clinical Trial of KJ101 for Gastric Mucus Removal","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B, 02659) announced that the National Medical Products Administration (NMPA) has cleared the company to initiate clinical trials of KJ101—its recombinant human chymotrypsin—for the dissolution and removal of gastric mucus during gastroscopy.</p>\n<p>KJ101 is positioned as China’s first recombinant human chymotrypsin produced via synthetic biology. Developed with the company’s proprietary yeast-fermentation platform, the drug candidate is designed to eliminate animal-derived inputs, offering higher purity, no animal-origin virus risk, no allergenicity, and minimal batch variability.</p>\n<p>Chymotrypsin, a protease capable of rapidly hydrolyzing proteins, is routinely applied in respiratory medicine, surgery, gastroenterology, and other departments to remove necrotic tissue and improve wound visibility. The new study focuses on enhancing visibility and efficiency during gastroscopy by clearing accumulated gastric mucus.</p>\n<p>In February 2025, KJ101 secured its initial Investigational New Drug (IND) approval for wound-healing indications such as burns, surgical incisions, pressure ulcers, and diabetic foot ulcers, and a Phase II trial (CTR20252263) commenced in July 2025.</p>\n<p>The company cautioned that clinical results, regulatory timelines, and eventual commercialization remain uncertain, and advised shareholders and potential investors to exercise prudence when trading its shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bao Pharma-B (02659) Receives NMPA Approval to Launch Clinical Trial of KJ101 for Gastric Mucus Removal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBao Pharma-B (02659) Receives NMPA Approval to Launch Clinical Trial of KJ101 for Gastric Mucus Removal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-12 12:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B, 02659) announced that the National Medical Products Administration (NMPA) has cleared the company to initiate clinical trials of KJ101—its recombinant human chymotrypsin—for the dissolution and removal of gastric mucus during gastroscopy.</p>\n<p>KJ101 is positioned as China’s first recombinant human chymotrypsin produced via synthetic biology. Developed with the company’s proprietary yeast-fermentation platform, the drug candidate is designed to eliminate animal-derived inputs, offering higher purity, no animal-origin virus risk, no allergenicity, and minimal batch variability.</p>\n<p>Chymotrypsin, a protease capable of rapidly hydrolyzing proteins, is routinely applied in respiratory medicine, surgery, gastroenterology, and other departments to remove necrotic tissue and improve wound visibility. The new study focuses on enhancing visibility and efficiency during gastroscopy by clearing accumulated gastric mucus.</p>\n<p>In February 2025, KJ101 secured its initial Investigational New Drug (IND) approval for wound-healing indications such as burns, surgical incisions, pressure ulcers, and diabetic foot ulcers, and a Phase II trial (CTR20252263) commenced in July 2025.</p>\n<p>The company cautioned that clinical results, regulatory timelines, and eventual commercialization remain uncertain, and advised shareholders and potential investors to exercise prudence when trading its shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1157341579","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157341579","pubTimestamp":1773288201,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B, 02659) announced that the National Medical Products Administration (NMPA) has cleared the company to initiate clinical trials of KJ101—its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"宝药业-B(02659)获NMPA批准开展KJ101用于胃粘液清除的临床试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B, 02659) announced that the National Medical Products Administration (NMPA) has cleared the company to initiate clinical trials of KJ101—its recombinant human chymotrypsin—for the dissolution and removal of gastric mucus during gastroscopy.\nKJ101 is positioned as China’s first recombinant human chymotrypsin produced via synthetic biology. Developed with the company’s proprietary yeast-fermentation platform, the drug candidate is designed to eliminate animal-derived inputs, offering higher purity, no animal-origin virus risk, no allergenicity, and minimal batch variability.\nChymotrypsin, a protease capable of rapidly hydrolyzing proteins, is routinely applied in respiratory medicine, surgery, gastroenterology, and other departments to remove necrotic tissue and improve wound visibility. The new study focuses on enhancing visibility and efficiency during gastroscopy by clearing accumulated gastric mucus.\nIn February 2025, KJ101 secured its initial Investigational New Drug (IND) approval for wound-healing indications such as burns, surgical incisions, pressure ulcers, and diabetic foot ulcers, and a Phase II trial (CTR20252263) commenced in July 2025.\nThe company cautioned that clinical results, regulatory timelines, and eventual commercialization remain uncertain, and advised shareholders and potential investors to exercise prudence when trading its shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157341579","isCrawlerRequest":true}